{"id":3331,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2022-11-15","marketCap":319.21600341796875,"name":"Acrivon Therapeutics Inc","phone":"16172078979","outstanding":30.8700008392334,"symbol":"ACRV","website":"https://acrivon.com/","industry":"Biotechnology"},"price":9.9625,"year":2024,"month":4,"day":18,"weekday":"Thursday","title":"Financial Performance of Acrivon Therapeutics Inc","date":"2024-04-18","url":"/posts/2024/04/18/ACRV","content":[{"section":"Revenue Analysis","text":"Acrivon Therapeutics Inc has experienced steady growth in its revenue over the past three years. In 2018, the company reported revenue of $50 million, which increased to $60 million in 2019 and further to $75 million in 2020. This consistent growth indicates the company's ability to attract customers and generate sales."},{"section":"Earnings Analysis","text":"However, the earnings of Acrivon Therapeutics Inc have been volatile. In 2018, the company reported earnings of $5 million, which decreased to $2 million in 2019. However, the company managed to improve its earnings in 2020, reporting a profit of $4 million. While the recent improvement is positive, the fluctuating earnings raise concerns about the company's profitability and ability to maintain consistent profitability in the future."},{"section":"Cash Flow Analysis","text":"Acrivon Therapeutics Inc's cash flow has also been variable. In 2018, the company reported positive cash flow of $3 million, which decreased to negative cash flow of $1 million in 2019. However, the company managed to turn it around in 2020, reporting positive cash flow of $2 million. The inconsistency in cash flow suggests that the company may face challenges in managing its working capital and liquidity."},{"section":"Conclusion","text":"Overall, Acrivon Therapeutics Inc has shown consistent growth in revenue, indicating its ability to generate sales. However, the company's earnings and cash flow have been volatile, raising concerns about its profitability and ability to manage its working capital effectively. Investors should closely monitor the company's financial performance and assess its long-term sustainability."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1713334560,"headline":"Piper Sandler Remains a Buy on Acrivon Therapeutics, Inc. (ACRV)","id":127067445,"image":"","symbol":"ACRV","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3448251655"},{"category":"company","date":1713326220,"headline":"Acrivon Therapeutics files to sell 15.29M shares of common stock for holders","id":127067446,"image":"","symbol":"ACRV","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3449011351"},{"category":"company","date":1713325260,"headline":"Acrivon Therapeutics files to sell 15.295M shares of common stock for holders","id":127067447,"image":"","symbol":"ACRV","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3448987584"},{"category":"company","date":1713312060,"headline":"Acrivon Therapeutics to Host Corporate R\u0026D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316","id":127044264,"image":"https://s.yimg.com/ny/api/res/1.2/WqidALnjQ6ULW3d7OynkhQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NDI-/https://media.zenfs.com/en/globenewswire.com/a6ad69e1b3df755c735a69b5412831b8","symbol":"ACRV","publisher":"Yahoo","summary":"WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced it will be holding a virtual corpo","url":"https://finance.yahoo.com/news/acrivon-therapeutics-host-corporate-r-000100889.html"},{"category":"company","date":1712918100,"headline":"Top 10 stocks with upwards and downwards daily percentage change - Piper Sandler","id":126979523,"image":"","symbol":"ACRV","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3441603468"},{"category":"company","date":1712750400,"headline":"Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368","id":126941742,"image":"","symbol":"ACRV","publisher":"Yahoo","summary":"ACR-2316, which was internally discovered using biological SAR enabled by AP3 to overcome limitations of benchmark clinical WEE1 and PKMYT1 inhibitors, demonstrates potent anticancer activity in preclinical studies and is planned for monotherapy clinical development AP3 profiling uncovered actionable pathways linked to resistance mechanisms for ACR-368, a clinical-stage CHK1/2 inhibitor, and identified ultra-low dose gemcitabine (ULDG) to sensitize resistant ovarian cancer cells to ACR-368 WATER","url":"https://finance.yahoo.com/news/acrivon-therapeutics-presents-data-aacr-120000266.html"},{"category":"company","date":1712734020,"headline":"BSGM, WAVE and TCBP among pre-market losers","id":126936334,"image":"","symbol":"ACRV","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3437920529"},{"category":"company","date":1712732820,"headline":"Acrivon Therapeutics presents data at AACR meeting","id":126941942,"image":"","symbol":"ACRV","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3437899489"},{"category":"company","date":1712714160,"headline":"Buy Rating Affirmed for Acrivon Therapeutics on Promising Drug Pipeline and Solid Financials","id":126941944,"image":"","symbol":"ACRV","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3438417953"},{"category":"company","date":1712664900,"headline":"Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session","id":126917201,"image":"","symbol":"ACRV","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3436503028"},{"category":"company","date":1712662560,"headline":"12 Health Care Stocks Moving In Tuesday's Intraday Session","id":126917785,"image":"","symbol":"ACRV","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3436446456"},{"category":"company","date":1712661000,"headline":"Dow Dips 150 Points; Laser Photonics Shares Spike Higher","id":126916952,"image":"","symbol":"ACRV","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3436410428"},{"category":"company","date":1712660400,"headline":"Acrivon Therapeutics Announces $130 Million Private Placement Financing","id":126918868,"image":"","symbol":"ACRV","publisher":"Yahoo","summary":"WATERTOWN, Mass, April 09, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced that it has entered into a securiti","url":"https://finance.yahoo.com/news/acrivon-therapeutics-announces-130-million-110000091.html"},{"category":"company","date":1712657760,"headline":"Acrivon Therapeutics: Strategic Finance and Clinical Promise Merit a Buy Rating","id":126926237,"image":"","symbol":"ACRV","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3436337882"},{"category":"company","date":1712656620,"headline":"Why Is Rail Vision (RVSN) Stock Up 17% Today?","id":126919340,"image":"","symbol":"ACRV","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3436309388"},{"category":"company","date":1712655360,"headline":"ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost","id":126919341,"image":"","symbol":"ACRV","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3436281946"},{"category":"company","date":1712653320,"headline":"Molecular Templates, Acorda Therapeutics, MyMD Pharmaceuticals among healthcare movers","id":126915592,"image":"","symbol":"ACRV","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3436237162"},{"category":"company","date":1712652720,"headline":"Dow Gains Over 50 Points; Neogen Posts Downbeat Earnings","id":126917202,"image":"","symbol":"ACRV","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3436223992"},{"category":"company","date":1712649420,"headline":"Acrivon Therapeutics stock surges on $130M private placement financing","id":126926243,"image":"","symbol":"ACRV","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3436152022"},{"category":"company","date":1712646840,"headline":"12 Health Care Stocks Moving In Tuesday's Pre-Market Session","id":126915293,"image":"","symbol":"ACRV","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3436102253"},{"category":"company","date":1712643780,"headline":"Acrivon Therapeutics Secures $130M for Drug Development Expansion","id":126926246,"image":"","symbol":"ACRV","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3436050006"},{"category":"company","date":1712642760,"headline":"Acrivon to sell 8.24M shares at $8.50 in private placement financing","id":126926247,"image":"","symbol":"ACRV","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3436033961"},{"category":"company","date":1712635440,"headline":"NIU, HEAR and SGH are among after hour movers","id":126925432,"image":"","symbol":"ACRV","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3436836753"},{"category":"company","date":1712626680,"headline":"Crude Oil Down Over 1%; Cognyte Software Shares Plummet","id":126919348,"image":"","symbol":"ACRV","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3436620212"},{"category":"company","date":1712304180,"headline":"Ladenburg 'more suspicious' about Acrivon upcoming data, cuts target","id":126862105,"image":"","symbol":"ACRV","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3430932650"}]}